Table 1.
PTB exclusion and CstF-64 inclusion in HCMV VRCs
| Staining | Subnuclear co-localization* | Dispersed | |||
|---|---|---|---|---|---|
| Complete | Partial | None | Nuclear | Cytoplasmic | |
| PTB and ppUL57 | |||||
| Mock infected | 100 % (264/264) | ||||
| Mock+PFA | 100 % (312/312) | ||||
| HCMV infected | 0 % (0/307) | 6.2 % (19/307) | 93.8 % (288/307) | ||
| HCMV+PFA | 76.4 % (370/484) | 23.6 % (114/484) | |||
| CstF-64 and ppUL57 | |||||
| Mock infected | 100 % (201/201) | ||||
| Mock+PFA | 100 % (312/312) | ||||
| HCMV infected | 0 % (0/298) | 97.0 % (289/298) | 3.0 % (9/298) | ||
| HCMV+PFA | 100 % (351/351) | ||||
*Co-localization of PTB or CstF-64 and ppUL57 (VRC marker) was measured in mock-infected or HCMV-infected G0-HFFs, either untreated or PFA treated at 96 h p.i. as described in Fig. 5.